2024-05-06 06:41:55 ET
Summary
- Teleflex is a medical device and instrument manufacturer with $3 billion in sales, supplying a wide range of products.
- The company saw strong growth in the 2010s as growth slowed down in recent years.
- Despite slower growth and concerns about GLP-1 drugs, Teleflex's lower valuation multiples make it an appealing investment opportunity.
In the summer of last year, I believed that shares of Teleflex ( TFX ) were flexing their muscles a bit, as operating momentum accelerated a bit again after a tougher 2022. The company announced its next bolt-on acquisition, although this strategic acquisition was rather expensive....
Read the full article on Seeking Alpha
For further details see:
Teleflex: Compelling, Despite Some Operational Hiccups